Barclays Maintains an 'Overweight' on Sequenom (SQNM); Lo Publishes Data on T-13/T-18 Detection
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Price: $2.39 --0%
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Sequenom (NASDAQ: SQNM), PT $9.
Barclays analyst says, "Following previous publications on non-invasive T-21 detection using sequencing methods, Dennis Lo's group published additional data on T-13/18 detection in the PLoS One journal last night. The study included 392 pregnancies, of which 25 and 37 were identified as T-13 and T-18, respectively. The group employed approaches designed to improve the sensitivity and specificity of T-13 /18 detection, including increasing the number of aligned sequence reads for each sample and correcting the GC-content bias inherent in the sequencing process using bioinformatics methods. This resulted in the sensitivity and specificity of T13 detection improving from 36% and 92.4% respectively, to 100% and 98.9%. The sensitivity and specificity of T18 detection improved from 73% and 97.2% respectively, to 91.9% and 98%."
For more ratings news on Sequenom click here and for the rating history of Sequenom click here.
Shares of Sequenom closed at $7.71 yesterday.
Barclays analyst says, "Following previous publications on non-invasive T-21 detection using sequencing methods, Dennis Lo's group published additional data on T-13/18 detection in the PLoS One journal last night. The study included 392 pregnancies, of which 25 and 37 were identified as T-13 and T-18, respectively. The group employed approaches designed to improve the sensitivity and specificity of T-13 /18 detection, including increasing the number of aligned sequence reads for each sample and correcting the GC-content bias inherent in the sequencing process using bioinformatics methods. This resulted in the sensitivity and specificity of T13 detection improving from 36% and 92.4% respectively, to 100% and 98.9%. The sensitivity and specificity of T18 detection improved from 73% and 97.2% respectively, to 91.9% and 98%."
For more ratings news on Sequenom click here and for the rating history of Sequenom click here.
Shares of Sequenom closed at $7.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
